-
3 weeks ago | 
jacc.org | Milton Packer |Michael R. Zile |Christopher M. Kramer |Masahiro Murakami
References1. "Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction". Circ Heart Fail . 2013;6:279-286. 2. "The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF". JACC Heart Fail . 2018;6:701-709. 3. "Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction". Circulation . 2017;136:6-19. 4.
-
2 months ago | 
onlinelibrary.wiley.com | Milton Packer |Javed Butler |Baylor Scott
Invited Editorial The win ratio for trials for heart failure: academic desperation or investigator decadence? Milton Packer, Corresponding Author Milton Packer Baylor University Medical Center, Dallas, TX, USA Imperial College, London, UK Corresponding author. Baylor Heart and Vascular Institute, Baylor University Medical Center, 621 North Hall Street, Dallas, TX 75226, USA.
-
Nov 18, 2024 | 
radcliffecvrm.com | Harriette Van Spall |Milton Packer |Rishi Sethi |Pravesh Vishwakarma
AHA Conference 2024 — New insights into the SUMMIT trial, investigating tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.
-
Nov 16, 2024 | 
healio.com | Regina Schaffer |Richard Smith |Erin D. Michos |Milton Packer
Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC Patients with the obesity phenotype represent the majority of those with HF with preserved ejection fraction — increased plasma volume and stressed blood volume, more concentric left ventricular remodeling, high prevalence of hypertension, more right ventricular dysfunction, increased epicardial fat thickness, higher total epicardial heart volume, and are more diuretic resistant.
-
Oct 22, 2024 | 
onlinelibrary.wiley.com | Henri Lu |Brian Claggett |Milton Packer |Baylor Heart
Supporting Information Filename Description ejhf3487-sup-0001-Figures.docxWord 2007 document , 1.3 MB Appendix S1. Supporting Information. References 1, , , , , , et al.; CHARM Investigators. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: Results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol 2012; 59: 1785–1795.
-
Sep 1, 2024 | 
onlinelibrary.wiley.com | Henri Lu |Brian Claggett |Milton Packer |Marc A. Pfeffer
Supporting Information Filename Description ejhf3414-sup-0001-Supinfo.docxWord 2007 document , 6.5 MB Appendix S1. Supporting Information. References 1, . Anemia and iron deficiency in heart failure: Current concepts and emerging therapies. Circulation 2018; 138: 80–98. https://doi.org/10.1161/CIRCULATIONAHA.118.030099 2, , , , , , et al.; CHARM Committees and Investigators.
-
Aug 30, 2024 | 
jamanetwork.com | Henri Lu |Brian Claggett |Milton Packer |Karl Swedberg
Key PointsQuestion What are the effects of sacubitril/valsartan on hospitalizations of any cause in patients with heart failure (HF)? Findings In this post hoc pooled analysis of the PARADIGM-HF and PARAGON-HF randomized clinical trials including 13 194 patients, sacubitril/valsartan significantly reduced the risk of all-cause hospitalization, primarily driven by lower rates of cardiac and pulmonary hospitalization.
-
Jul 1, 2024 | 
jacc.org | Milton Packer |Joao Ferreira |Javed Butler |Gerasimos Filippatos
IntroductionSodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular death and hospitalization for heart failure in patients with heart failure, both with reduced and preserved ejection fraction.1 Potential mechanisms of action have been elucidated in both experimental models and in the clinical setting.
-
May 28, 2024 | 
academic.oup.com | Baylor Heart |John F |Johann Bauersachs |Milton Packer
Heart failure with reduced ejection fraction (HFrEF) entails a poor prognosis if not adequately treated.
-
May 13, 2024 | 
ahajournals.org | Javed Butler |Norman Stockbridge |Milton Packer
REFERENCES1. Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.Eur Heart J. 2012; 33:176–182. doi: 10.1093/eurheartj/ehr352CrossrefMedlineGoogle Scholar2. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, . The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.Nat Med.
